Cargando…

A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic, remitting, and relapsing, inflammatory disease involving multiple organs, which exhibits abnormalities of both the innate and adaptive immune responses. A limited number of transcriptomic studies have characterized the gene pathways involved in SLE in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yupeng, Higgs, Richard E., Hoffman, Robert W., Dow, Ernst R., Liu, Xiong, Petri, Michelle, Wallace, Daniel J., Dörner, Thomas, Eastwood, Brian J., Miller, Bradley B., Liu, Yushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886858/ https://www.ncbi.nlm.nih.gov/pubmed/31790472 http://dx.doi.org/10.1371/journal.pone.0225651

Ejemplares similares

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
por: Dörner, Thomas, et al.
Publicado: (2020)

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab
por: Hoffman, Robert W., et al.
Publicado: (2017)

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
por: Richter, Patricia, et al.
Publicado: (2022)

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent
por: Alunno, Alessia, et al.
Publicado: (2019)

JAK3-STAT pathway blocking benefits in experimental lupus nephritis
por: Ripoll, Èlia, et al.
Publicado: (2016)

Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
por: Morand, Eric, et al.
Publicado: (2023)

Specificity of the STAT4 Genetic Association for Severe Disease Manifestations of Systemic Lupus Erythematosus
por: Taylor, Kimberly E., et al.
Publicado: (2008)

Unmet medical needs in systemic lupus erythematosus
por: Lateef, Aisha, et al.
Publicado: (2012)

Erratum to: JAK3-STAT pathway blocking benefits in experimental lupus nephritis
por: Ripoll, Èlia, et al.
Publicado: (2016)

Advances in drug therapy for systemic lupus erythematosus
por: Wallace, Daniel J
Publicado: (2010)

Stat1 and phosphorylated Stat1 are increased in lymphocytes and monocytes of patients with systemic lupus erythematosus
por: Aringer, M, et al.
Publicado: (2005)

Analysis of B-cell subpopulations in systemic lupus erythematosus
por: Dorner, T, et al.
Publicado: (2003)

B cells, BAFF/zTNF4, TACI, and systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2001)

Polymorphism in STAT4 Increase the Risk of Systemic Lupus Erythematosus: An Updated Meta-Analysis
por: Shancui-zheng,, et al.
Publicado: (2022)

Lung cancer in systemic lupus erythematosus
por: Kale, M, et al.
Publicado: (2012)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

An integrative Bayesian network approach to highlight key drivers in systemic lupus erythematosus
por: Maleknia, Samaneh, et al.
Publicado: (2020)

Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus
por: Kotyla, Przemysław, et al.
Publicado: (2022)

Toll-like receptor signalling in B cells during systemic lupus erythematosus
por: Fillatreau, Simon, et al.
Publicado: (2020)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus
por: Petri, Michelle A, et al.
Publicado: (2020)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Nonlymphoma hematological malignancies in systemic lupus erythematosus
por: Lu, M, et al.
Publicado: (2012)

Two Major Autoantibody Clusters in Systemic Lupus Erythematosus
por: Ching, Kathryn H., et al.
Publicado: (2012)

Understanding the genetics of systemic lupus erythematosus using Bayesian statistics and gene network analysis
por: Nam, Seoung Wan, et al.
Publicado: (2020)

Clinical and histopathological features of myositis in systemic lupus erythematosus
por: Tiniakou, Eleni, et al.
Publicado: (2022)

JAK-STAT Signalling Pathway in Cancer
por: Brooks, Andrew J., et al.
Publicado: (2020)

Systemic lupus erythematosus.
por: Richardson, J.
Publicado: (1969)

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2020)

Development of a systemic lupus erythematosus cardiovascular risk equation
por: Petri, Michelle A, et al.
Publicado: (2019)

Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
por: Furqan, Muhammad, et al.
Publicado: (2013)

Systemic lupus erythematosus
por: Manson, Jessica J, et al.
Publicado: (2006)

A JAK/STAT invasion
por: Wells, William A.
Publicado: (2002)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

The Drosophila JAK-STAT pathway
por: Zeidler, Martin P, et al.
Publicado: (2013)

Evolution of the JAK-STAT pathway
por: Liongue, Clifford, et al.
Publicado: (2013)

The JAK-STAT pathway at 20
por: Darnell, Jr., James E.
Publicado: (2012)

JAK-STAT in lymphoproliferative disorders
por: Rabadan, Raul, et al.
Publicado: (2015)

The JAK/STAT Pathway Is Involved in Synaptic Plasticity
por: Nicolas, Céline S., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mbese6geta7k5af8i7k2r6o6iq